Tau mutations as a novel risk factor for cancer—letter

the LEFFTDS Consortium

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)6523-6524
Number of pages2
JournalCancer Research
Volume78
Issue number22
DOIs
StatePublished - Nov 15 2018

Funding

The LEFFTDS study is supported by the following NIH grants: U01 AG045390-01A1, U54 NS092089, U24 AG021886, U01 AG016976, and P50 NS072187 (to B. Boeve, H. Rosen, A. Boxer, and Z.K. Wszolek). A.B. Deutschl€ander reports receiving a commercial research grant from Allergan Educational Grant. H.J. Rosen reports receiving a commercial research grant from Biogen Pharmceuticals and is a consultant/advisory board member for Ionis Pharmaceuticals and Wave Pharmaceuticals. A.L. Boxer reports receiving a commercial research grant from Genentech, Roche, Biogen, BMS, Lilly and has ownership interest (including stocks and patents) in Alector, Aeton Therapeutics. He is a consultant/advisory board member for Abbvie, Arkuda, Merck, Novartis, Samumed, Toyama, UCB, Asceneuro, and Wave. No potential conflicts of interest were disclosed by the other authors.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this